A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles to find a sustainable business model. Once occupying a value of $6bn, the company diversified beyond DNA testing and started a drug research business along with more specific diagnostic insights for customers.

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs to raise more mon­ey to con­tin­ue …